CoChat
Sign Up
Cited by 330

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Colon Targeted Drug Delivery Systems: A Review on Primary and Novel Approaches

Philip, Anil, Philip, Betty·2010·Oman Medical Journal
DOI 10.5001/omj.2010.24
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5001/omj.2010.24

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 67

  1. [1]1. Philip AK, Dabas S, Pathak K. Optimized prodrug approach: a means for achieving enhanced anti-inflammatory potential in experimentally induced colitis. J Drug T arget 2009 Apr;17(3):235-241.
  2. [2]2. Oluwatoyin AO, John TF. In vitro evaluation of khaya and albizia gums as compression coating for drug targeting to the colon. J Pharm Pharmacol 2005;57:63-168.
  3. [3]3. Akala EO, Elekwachi O, Chase V, Johnson H, Lazarre M, Scott K. Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. Drug Dev Ind Pharm 2003 Apr;29(4):375-386.
  4. [4]4. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003 Jan-Apr;6(1):33-66.
  5. [6]6. Watts P, Illum L. Colonic drug delivery. Drug Dev Ind Pharm 1997;23:893913 .
  6. [7]7. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharm 1985;25:191-197 .
  7. [9]9. Reddy SM, Sinha VR, Reddy DS. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs. Drugs Today (Barc) 1999 Jul;35(7):537-580.
  8. [10]10. Philip AK, Dubey RK, Pathak K. Optimizing delivery of flurbiprofen to the colon using a targeted prodrug approach. J Pharm Pharmacol 2008 May;60(5):607-613.
  9. [12]12. McLeod AD, Friend DR, Tozer TN. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J Pharm Sci 1994 Sep;83(9):1284-1288.
  10. [14]14. Antonin KH, Rak R, Bieck PR, Preiss R, Schenker U, Hastewell J, et al. The absorption of human calcitonin from the transverse colon of man. Int J Pharm 1996;130(1):33-39 .
  11. [15]15. Fara JW. Novel Drug Delivery and its Therapeutic Application. In: Presscot LF, Nimmo WS, editors. Colonic drug absorption and metabolism. Wiley: Chichester, 1989; 103-120.
  12. [17]17. Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem 1984 Mar;27(3):261-266.
  13. [18]18. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst 1995;12(2-3):101-149.
  14. [20]20. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2001;18(5):433-458.
  15. [21]21. Ashord M, Fell JT, Attwood D, Sharma H, Woodhead P. An evaluation of pectin as a carrier for drug targeting to the colon. J Control Release 1993;26:213-220 .
  16. [22]22. Fukui E, Miyamura N, Kobayashi M. An in vitro investigation of the suitability of presscoated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobicn additives in the outer shell for colon targeting. J Control Rel 200; 70:97-107.
  17. [23]23. Gazzaniga A, Iamartino P, Maffino G, Sangalli ME. Oral delayed release system for colonic specific drug delivery. Int J Pharm 1994;108:77-83 .
  18. [24]24. Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm 2000 Aug;204(12):7-15.
  19. [25]25. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992 Jan;102(1):102-108.
  20. [26]26. von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993 Oct;329(15):1073-1078.
  21. [27]27. Kinget R, Kalala W, Vervoort L, van den Mooter G. Colonic drug targeting. J Drug Target 1998;6(2):129-149.
  22. [28]28. Hita V, Singh R, Jain SK. Colonic targeting of metronidazole using azo aromatic polymers, development and characterization. Drug Deliv 1997;4:1922 .
  23. [29]29. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos 1990 Aug-Sep;11(6):465-475.
  24. [31]31. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 1973 Dec;25(4):451-523.
  25. [32]32. Peters R, Kinget R. Film-forming polymers for colonic drug deliver: Synthesis and physical and chemical properties of methyl derivatives of Eudragit S. Int J Pharm 1993;94:125-134 .
  26. [33]33. Huang SI, Bansleben DA, Knox JR. Biodegradable polymers: Chymotrypsin degradation of low molecular weight poly (ester-urea) containing phenylalanine. J Appl Polym Sci 1979;23:429-437 .
  27. [34]34. Swift G. Biodegradable polymers in the environment: are they really biodegradable. Proc ACS Div Poly Mat Sci Eng 1992; 66:403-404.
  28. [35]35. Ratner BD, Gladhill KW, Horbett TA. Analysis of in vitro enzymatic and oxidative degradation of polyurethanes. J Biomed Mater Res 1988 Jun;22(6):509-527.
  29. [36]36. Hergenrother RW, Wabewr HD, Cooper SL. The effect of chain extenders and stabilizers on the in vivo stability of polyurethanes. J Appl Biomater 1992;3:17-22 .
  30. [38]38. Friend DR, Chang GW. Drug glycosides: potential prodrugs for colonspecific drug delivery. J Med Chem 1985 Jan;28(1):51-57.
  31. [39]39. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003 Jan;18(1):3-18.
  32. [40]40. Khan AK, Piris J, Truelone SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:895-896.
  33. [41]41. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983 Jul;28(7):609-615.
  34. [42]42. Shibasaki J, Inoue Y, Kadosaki K, Sasaki H, Nakamura J. Hydrolysis of salicyluric acid in rabbit intestinal microorganisms. J Pharmacobiodyn 1985 Dec;8(12):989-995.
  35. [43]43. Nakamura J, Kido M, Nishida K, Sasaki H. Hydrolysis of salicylic acid tyrosine salicylic acid-methionine prodrug in rabbits. Int J Pharm 1992;87:59-66 .
  36. [44]44. Nakamura J, Tagami C, Nishida K, Sasaki H. Unequal hydrolysis of salicylic acid-D-alanine and salicylic acid-L-alanine conjugate in rabbit intestinal microorganisms. Chem Pharm Bull (Tokyo) 1992b Feb;40(2):547-549.
  37. [45]45. Jung YJ, Lee JS, Kim HH, Kim YM, Han SK. Synthesis and evaluation of 5-aminosalicyl-glycine as a potential colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 1998 Apr;21(2):174-178.
  38. [46]46. Simpkins JW, Smulkowski M, Dixon R, Tuttle R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 1988 Jan;244(1):195-205.
  39. [47]47. Cui N, Friend DR, Fedorak RN. A budesonide prodrug accelerates treatment of colitis in rats. Gut 1994 Oct;35(10):1439-1446.
  40. [48]48. Van den Mooter G, Samyn C, Kinget R. In vivo evaluation of a colon-specific drug delivery system: an absorption study of theophylline from capsules coated with azo polymers in rats. Pharm Res 1995 Feb;12(2):244-247.
  41. [49]49. Saffron M, Kumar GS, Savariora C, Burnham JC, Williams F, Neekers DC. A new approach to the oral administration of insulin and other peptide drugs. Sci 1986;233:1081-1084 .
  42. [50]50. Saffran M, Bedra C, Kumar GS, Neckers DC. Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J Pharm Sci 1988 Jan;77(1):33-38.
  43. [51]51. Saffran M, Field JB, Peña J, Jones RH, Okuda Y. Oral insulin in diabetic dogs. J Endocrinol 1991 Nov;131(2):267-278.
  44. [52]52. Shanta KL, Ravichandran P, Rao KP. Azopolymeric hydrogels for colon targeted drug delivery. Biomat 1995;16:1313-1318 .
  45. [53]53. Tozaki H, Fujita T, Komoike J, Kim SI, Terashima H, Muranishi S, et al. Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J Pharm Pharmacol 1999 Mar;51(3):257-261.
  46. [54]54. Chavan MS, Sant VP, Nagarsenker MS. Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in-vitro evaluation. J Pharm Pharmacol 2001 Jun;53(6):895-900.
  47. [55]55. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997 Sep;86(9):1016-1021.
  48. [56]56. Aiedeh K, Taha MO. Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered colon specific drug delivery system. Arch Pharm Res 1999;332:103-107 .
  49. [57]57. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. Pharm Res 1993 Feb;10(2):258-263.
  50. [58]58. Wakerly Z, Fell J, Attwood D, Parkins D. Studies on amidated pectins as potential carriers in colonic drug delivery. J Pharm Pharmacol 1997 Jun;49(6):622-625.
  51. [59]59. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci 2000 Mar;10(1):43-52.
  52. [60]60. Rubinstin A, Nakar D, Sintov A. Chondroitin sulphate: A potential biodegradable carrier for colon-specific drug delivery. Int J Pharm 1992;84:141-150 .
  53. [61]61. Shun YL, Ayres JW. Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm Res 1992;9:714-790.
  54. [62]62. Takaya T, Niwa K, Muraoka M, Ogita I, Nagai N, Yano R, et al. Importance of dissolution process on systemic availability of drugs delivered by colon delivery system. J Control Release 1998 Jan;50(1-3):111-122.
  55. [63]63. Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release 1998 Mar;52(1-2):119-129.
  56. [64]64. Jeong Y, Ohno T, Hu Z, Yoshikawa Y, Shibata N, Nagata S, Takada K. Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method. J Control Rel 71(2):175-182.
  57. [65]65. Hay DJ, Sharma H, Irving MH. Spread of steroid-containing foam after intrarectal administration. Br Med J 1979 Jun;1(6180):1751-1753.
  58. [68]68. Katsuma M, Watanabe S, Takemura S, Sako K, Sawada T, Masuda Y, et al. Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers. J Pharm Sci 2004 May;93(5):1287-1299.
  59. [69]69. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 2002 Mar;235(1-2):1-15.
  60. [71]71. Swanson D, Barclay B, Wong P, Theeuwes F. Nifedipine gastrointestinal therapeutics system. Am J Med 1987;8(6):3 .
  61. [72]72. Philip AK, Pathak K. Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility. AAPS PharmSciTech 2006;7(3):56.
  62. [73]73. Philip AK, Pathak K. In situ-formed asymmetric membrane capsule for osmotic release of poorly water-soluble drug. PDA J Pharm Sci Technol 2007 Jan-Feb;61(1):24-36.
  63. [74]74. Philip AK, Pathak K, Shakya P. Asymmetric membrane in membrane capsules: a means for achieving delayed and osmotic flow of cefadroxil. Eur J Pharm Biopharm 2008 Jun;69(2):658-666.
  64. [75]75. Philip AK, Pathak K. Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled, and level A IVIVC for poorly water-soluble drug. Drug Dev Ind Pharm 2008 Jul;34(7):735-743.
  65. [76]76. Ahmed IS. Effect of simulated gastrointestinal conditions on drug release from pectin/ethylcellulose as film coating for drug delivery to the colon. Drug Dev Ind Pharm 2005 May;31(4-5):465-470.
  66. [77]77. Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm 2002 Jan;231(1):83-95.
  67. [78]78. Mooter VG, Kinget R. Oral colon-specific drug delivery: A review. Drug Deliv 1995;2:881-931.

Cited by

Sorted by citations

See all 330

Metadata

Authors
Philip, A., & Philip, B.
Venue
Oman Medical Journal
Publisher
Oman Medical Journal
Published
2010-04
Volume
25
Issue
2
Pages
70-78
ISSN
2070-5204
DOI
10.5001/omj.2010.24
Cited by
330
References
1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review